Glucagon like peptide-1 promotes satiety and suppresses energy intake in humans
BPC-157 Timing, Empty Stomach, and Days Per Week Empty stomach One thing we noted was that orally, BPC-157 was taken consistently on an empty stomach
Tirzepatide (Mounjaro/Zepbound) Primary uses: Weight loss (more effective than semaglutide) Type 2 diabetes Appetite control Typical dosing: Week 1-4: 2.5mg once weekly Week 5-8: 5mg once weekly Week 9-12: 7.5mg once weekly Week 13-16: 10mg once weekly Week 17-20: 12.5mg once weekly Week 21+: 15mg once weekly (max) Administration: Subcutaneous injection, once weekly Special notes: Dual GLP-1/GIP agonist Slightly better weight loss than semaglutide FDA-approved Similar side effects to semaglutide AOD 9604 (Fragment 176-191) Primary uses: Fat loss (especially stubborn fat) No appetite suppression Body recomposition Typical dosing: 300-600mcg daily Fasted morning injection preferred Duration: 12-16 weeks Administration: Subcutaneous injection Special notes: Fragment of growth hormone (fat-burning portion only) No effect on blood sugar or insulin Targets stubborn fat areas Good for athletes who can't suppress appetite Learn more in our AOD 9604 guide and HGH Fragment calculator
Do I need to take a GLP-1 medication forever
While more large-scale trials are forthcoming, real-world usage and prior studies indicate that bremelanotide can safely improve male sexual function in at least a significant minority of patients
The GLP-1 (Glucagon-Like Peptide-1) Receptor Agonist Market is undergoing a paradigm shift, transforming from a niche therapeutic class primarily used in type 2 diabetes management to a multi-billion-dollar market at the heart of the global obesity epidemic
